Table 3.
Associations between self-reported MG severity and MGQOL15 scale scores (z-transformed continuous outcome).
| M1: self-reported severity N=1053 |
M2: additionally adjusted for depression N=1049 |
M3: additionally adjusted for gender N= 1049 |
M4: additionally adjusted for other variablesa N= 975 |
|
|---|---|---|---|---|
| Self-reported MG severity | ||||
| Moderate vs. mild | 13.16 (11.63–14.69) | 9.40 (8.07–10.72) | 8.99 (7.68–10.30) | 8.09 (6.75–9.44) |
| Severe vs. mild | 18.26 (15.92–20.60) | 15.37 (13.39–17.35) | 15.09 (13.15–17.04) | 14.36 (12.23–16.48) |
| Depression (HADS) | ||||
| mild vs. healthy* | – | 11.56 (9.85–13.27) | 11.67 (9.98–13.35) | 11.51 (9.78–13.23) |
| moderate vs. healthy | – | 16.81 (14.79–18.83) | 16.82 (14.83–18.81) | 17.00 (15.01–19.00) |
| severe vs. healthy | – | 21.37 (17.71–25.02) | 21.69 (18.10–25.29) | 21.05 (17.33–24.77) |
| gender | ||||
| Female vs. male | – | – | 3.54 (2.36–4.72) | 2.86 (1.48–4.24) |
| Other autoimmune disorder | 1.58 (0.11–3.05) | |||
| Rituximab or IVIG intake | 3.83 (1.83–5.84) | |||
| thymectomy | − 0.85 (− 2.23–0.51) | |||
| Adj R2 | 0,264 | 0,490 | 0,506 | 0,560 |
Stepwise Linear regression analysis. Estimated marginal means with 95%CI for MGQOL15 scale scores. *healthy = no depression according to HADS.
aM4: Additionally adjusted for thymectomy, other autoimmune disease, cardiovascular disease, IVIG/Rituximab, myasthenic crisis/exacerbation, duration, disease latency age, education, marital status.